Jean-Luc Harousseau

发表

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

Anthony Boral, Hartmut Goldschmidt, Mario Boccadoro, 2007, Blood.

Proteasome inhibitors in multiple myeloma: 10 years later.

Michele Cavo, Philippe Moreau, A. Palumbo, 2012, Blood.

Prognostic significance of copy-number alterations in multiple myeloma.

Cheng Li, Kenneth C. Anderson, Catherine Charbonnel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.

Serge Leyvraz, Herve Avet-Loiseau, Philippe Moreau, 2006, Blood.

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.

Pierre Fenaux, R. Stone, P. Fenaux, 2007, Blood.

Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma (MM): Results of a Phase 3 Study (MM-010).

Jerome B. Zeldis, M. Dimopoulos, J. Zeldis, 2005 .

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Alessandro Corso, Robin Foà, M. Dimopoulos, 2007, The New England journal of medicine.

Overexpression of Her2/neu is observed in one third of adult acute lymphoblastic leukemia patients and is associated with chemoresistance in these patients.

P. Chevallier, H. Avet-Loiseau, J. Harousseau, 2004, Haematologica.

A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.

Bob Löwenberg, Jason Gotlib, Yixin Wang, 2007, Blood.

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

Kenneth C. Anderson, Benjamin Djulbegovic, Bart Barlogie, 2003, British journal of haematology.

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Hartmut Goldschmidt, Mario Boccadoro, David Irwin, 2005, The New England journal of medicine.

A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

J. Rossi, R. Bataille, N. Ifrah, 1996 .

Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia

David C. Atkins, Bob Löwenberg, David Atkins, 2007, Clinical Cancer Research.

Autologous hematopoietic stem-cell transplantation for multiple myeloma.

Philippe Moreau, P. Moreau, J. Harousseau, 2009, The New England journal of medicine.

Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design

David Khayat, Christian Puozzo, D. Khayat, 2004, Cancer Chemotherapy and Pharmacology.

Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy

Augustin Ferrant, Chantal Doyen, J. Rossi, 2006 .

Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome.

Laurence Lodé, Catherine Charbonnel, Wilfried Gouraud, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.